Brief: Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026
29/09/2025 23:22
Sept 29 (Reuters) - AnaptysBio Inc ANAB.O: ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026 ANAPTYS ANNOUNCES INTENT TO SEPARATE BIOPHARMA OPERATIONS FROM SUBSTANTIAL ROYALTY ASSETS BY YEAR-END 2026 ANAPTYSBIO INC - BIOPHARMA CO TO FOCUS ON IMMUNOLOGY THERAPEUTICS ANAPTYSBIO INC - DANIEL FAGA ANTICIPATED TO BE CEO OF BIOPHARMA CO ANAPTYSBIO INC - UPON DEAL CLOSE, ROYALTY MANAGEMENT COMPANY TO MANAGE ROYALTIES INCLUDING JEMPERLI & IMSIDOLIMAB ANAPTYSBIO: UPON COMPLETION, BIOPHARMA CO TO LAUNCH WITH ADEQUATE CAPITAL TO FUND OPERATIONS FOR AT LEAST 2 YEARS Source text: ID:nGNX6VdsNH Further company coverage: ANAB.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on AnaptysBio
See all newsU.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged